PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment of Otodectes cynotis in cats.

Abstract The efficacy of a new spot-on formulation of selamectin/sarolaner was evaluated against induced Otodectes cynotis infestations in cats in two randomized, blinded studies. Fourteen and 16 cats were randomly assigned to treatment groups in Studies 1 and 2, respectively. On Day 0, animals were either treated with placebo or with the spot-on formulation at the minimal dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight. Treatments were administered topically at the base of the neck. Presence of live mites was evaluated 14days after treatment administration by otoscopic examination and total live mite counts (adults plus immature) were conducted on Day 30 by ear lavage. Efficacy was calculated based on the reduction of mean total live mite counts on Day 30 in the selamectin/sarolaner-treated group versus the placebo-treated group. There were no treatment-related adverse reactions during the studies, apart from one cat in each treatment group with alopecia at the administration site. In both studies combined, live mites were present on Day 14, in 14 out of 15 cats in the placebo-treated groups and in 2 out of 15 cats in the selamectin/sarolaner-treated groups. On Day 30, the arithmetic mean live mite counts were 576.9 and 875.8 in the placebo-treated groups and 5.8 and 4.7 in the selamectin/sarolaner-treated groups, in Studies 1 and 2, respectively. The live mite counts were significantly (P≤0.0021) lower in the selamectin/sarolaner-treated groups compared to the placebo-treated groups with efficacies of 99.2% and 99.3%, in Studies 1 and 2 respectively. A single administration of a new spot-on formulation of selamectin/sarolaner at the minimum dose was safe and highly efficacious in the treatment of ear mite infestations in cats.
PMID
Related Publications

Efficacy of a new spot-on formulation of selamectin plus sarolaner against four common tick species infesting cats in Europe.

Efficacy of a new spot-on formulation of selamectin plus sarolaner for cats against adult Ctenocephalides felis, flea egg production and adult flea emergence.

Efficacy and safety of a new spot-on formulation of selamectin plus sarolaner in the treatment of naturally occurring flea and tick infestations in cats presented as veterinary patients in Europe.

Efficacy and speed of kill of a new spot-on formulation of selamectin plus sarolaner against flea infestations in cats.

Speed of kill of a new spot-on formulation of selamectin plus sarolaner for cats against induced infestations with Ixodes ricinus.

Authors

Mayor MeshTerms
Keywords

Cat

Ear mites

Otodectes cynotis

Revolution

Sarolaner

Selamectin

Stronghold

Journal Title veterinary parasitology
Publication Year Start




PMID- 28395753
OWN - NLM
STAT- MEDLINE
DA  - 20170411
DCOM- 20170418
LR  - 20170418
IS  - 1873-2550 (Electronic)
IS  - 0304-4017 (Linking)
VI  - 238 Suppl 1
DP  - 2017 Apr
TI  - Efficacy of a new spot-on formulation of selamectin plus sarolaner in the
      treatment of Otodectes cynotis in cats.
PG  - S27-S30
LID - S0304-4017(17)30076-6 [pii]
LID - 10.1016/j.vetpar.2017.02.029 [doi]
AB  - The efficacy of a new spot-on formulation of selamectin/sarolaner was evaluated
      against induced Otodectes cynotis infestations in cats in two randomized, blinded
      studies. Fourteen and 16 cats were randomly assigned to treatment groups in
      Studies 1 and 2, respectively. On Day 0, animals were either treated with placebo
      or with the spot-on formulation at the minimal dose of 6.0mg selamectin and 1.0mg
      sarolaner per kg bodyweight. Treatments were administered topically at the base
      of the neck. Presence of live mites was evaluated 14days after treatment
      administration by otoscopic examination and total live mite counts (adults plus
      immature) were conducted on Day 30 by ear lavage. Efficacy was calculated based
      on the reduction of mean total live mite counts on Day 30 in the
      selamectin/sarolaner-treated group versus the placebo-treated group. There were
      no treatment-related adverse reactions during the studies, apart from one cat in 
      each treatment group with alopecia at the administration site. In both studies
      combined, live mites were present on Day 14, in 14 out of 15 cats in the
      placebo-treated groups and in 2 out of 15 cats in the
      selamectin/sarolaner-treated groups. On Day 30, the arithmetic mean live mite
      counts were 576.9 and 875.8 in the placebo-treated groups and 5.8 and 4.7 in the 
      selamectin/sarolaner-treated groups, in Studies 1 and 2, respectively. The live
      mite counts were significantly (P</=0.0021) lower in the
      selamectin/sarolaner-treated groups compared to the placebo-treated groups with
      efficacies of 99.2% and 99.3%, in Studies 1 and 2 respectively. A single
      administration of a new spot-on formulation of selamectin/sarolaner at the
      minimum dose was safe and highly efficacious in the treatment of ear mite
      infestations in cats.
CI  - Copyright (c) 2017 Zoetis Services LLC. Published by Elsevier B.V. All rights
      reserved.
FAU - Becskei, Csilla
AU  - Becskei C
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20,
      Zaventem, B-1930, Belgium. Electronic address: [email protected]
FAU - Reinemeyer, Craig
AU  - Reinemeyer C
AD  - East Tennessee Clinical Research Inc., 80 Copper Ridge Farm Road, Rockwood, TN
      37854, USA.
FAU - King, Vickie L
AU  - King VL
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
FAU - Lin, Dan
AU  - Lin D
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20,
      Zaventem, B-1930, Belgium.
FAU - Myers, Melanie R
AU  - Myers MR
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
FAU - Vatta, Adriano F
AU  - Vatta AF
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Vet Parasitol
JT  - Veterinary parasitology
JID - 7602745
RN  - 0 (Antiparasitic Agents)
RN  - 0 (Isoxazoles)
RN  - 70288-86-7 (Ivermectin)
RN  - A2669OWX9N (selamectin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Antiparasitic Agents/administration & dosage
MH  - Cat Diseases/*drug therapy
MH  - Cats
MH  - Female
MH  - Isoxazoles/*administration & dosage
MH  - Ivermectin/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Mite Infestations/drug therapy/*veterinary
MH  - Parasite Load
MH  - Psoroptidae
MH  - Random Allocation
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cat
OT  - Ear mites
OT  - Otodectes cynotis
OT  - Revolution
OT  - Sarolaner
OT  - Selamectin
OT  - Stronghold
EDAT- 2017/04/12 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/12/15 [received]
PHST- 2017/01/23 [revised]
PHST- 2017/02/23 [accepted]
AID - S0304-4017(17)30076-6 [pii]
AID - 10.1016/j.vetpar.2017.02.029 [doi]
PST - ppublish
SO  - Vet Parasitol. 2017 Apr;238 Suppl 1:S27-S30. doi: 10.1016/j.vetpar.2017.02.029.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>